ACRS Stock Analysis: Buy, Sell, or Hold?
ACRS - Aclaris Therapeutics, Inc.
$4.32
-0.20 (-4.42%)
▼
5d:
-12.73%
30d:
+1.65%
90d:
+32.52%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
ACRS is down 8.3% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 245 OI. Call ratio: 98% View Scanner →
Strength: 9.0/10
Get Alerted When ACRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called ACRS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ACRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ACRS is currently trading at $4.32, which is considered extended relative to its 30-day fair value range of $3.99 to $4.75.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is currently testing key support at $4.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.67 (+113.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is currently testing key support at $4.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.67 (+113.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.99 -
$4.75
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 113.9% below Wall St target ($9.67)
- CAUTION: 5-day price weakness (-12.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.99 -
$4.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.38
Resistance Level
$5.15
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.23
Wall Street Target
$9.67
(+113.9%)
Revenue Growth (YoY)
37.2%
Share & Embed Analysis
Last updated: May 18, 2026 9:59 AM ET
Data refreshes hourly during market hours. Next update: 10:59 AM
Data refreshes hourly during market hours. Next update: 10:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
ACRS is a key holding in these high-performance investment strategies.
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$242 | 64 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
